Related by context. All words. (Click for frequent words.) 57 HORIZONS 57 DA VINCI 56 multicentre randomized 55 multicenter randomized clinical 55 EXCITE 55 PRELUDE 55 Asthma Intervention 54 STENT 54 ASTEROID 54 SWOG 54 ACCLAIM 54 BLOSSOM 53 phase IIIb 53 Phase Ib clinical 53 OLYMPIA registry 53 MATCHED 53 ALLEGRO 53 TRIUMPH 53 SATURN 52 POISE 52 SPIRIT FIRST 52 ONTARGET 52 MONT BLANC 52 PATHWAY 52 MEND CABG 52 CABANA 52 PREVAIL 51 ACRIN 51 FIREBIRD 51 TMC# C# 51 fosbretabulin 51 PREDICT 51 ACCOMPLISH 51 STUDY RESULTS 51 PROCEED 50 NO# [002] 50 PROWESS 50 Cholesterol Treatment Trialists 50 AIM HIGH 50 COMPANION 50 CABERNET 50 CONCERTO 50 Acute Myocardial Infarction 50 INSPIRE 50 STEEPLE 50 Prospective Randomized 50 STELLAR 50 phase IIb study 50 WE WILL CONTINUE TO 50 RADIANT 50 REVIVE 50 PHASE III 50 PROPEL 50 EMBRACE 50 placebo controlled clinical 50 ACCELERATE 50 MICROSCOPE 50 SIMPADICO 50 randomized Phase III 50 CALGB 50 ASSERT 49 CARDIOLOGY 49 Phase Ib Clinical Trial 49 Referenced EEG 49 RE LY 49 NCIC CTG 49 TAPAS 49 PRECISE 49 HYVET 49 CARE HF 49 PFO migraine 49 ENVISION 49 prospective multicentre 49 subanalysis 49 ENABLE 49 CHAMPION PCI 49 DYNA 49 SEQUEL 49 UNLOAD 48 ILLUMINATE 48 ARBITER 6 48 TAXUS ATLAS 48 INFORM 48 PARADIGM 48 COMPARE 48 PROACT 48 CLARITY 48 IMPRESS 48 NATAL 48 SQUARED 48 CONNECTS 48 Schizophrenia Treatment 48 Optical Coherence Tomography 48 TRANSCEND 48 Aortic Dissection 48 ACCELERATION 48 MEND CABG II 48 Resynchronization 48 CONDOR 48 PHASE ONE 48 Randomized Evaluation 48 Intervention Effectiveness 48 MADIT 48 Aggressive Reduction 48 CRLX# 48 Sequenced Treatment Alternatives 48 CUSTOM II 48 ON #.Na 48 CADRE 48 ATTAIN 48 CELLO 48 EchoCRT 48 RIBBON 48 RIVA D. 48 randomized multicenter 48 COMMIT 48 RESTORE CLI 48 LISTENER 48 Randomized controlled 48 multicenter prospective 48 ELEVATE 48 CURRENT OASIS 7 48 Phase 2b kidney transplant 47 DIAGNOSTIC 47 PRoFESS 47 BLOOM 47 Peripheral Arterial 47 ENDEAVOR III 47 registrational 47 ATTRACT 47 GUSTO 47 DAY BEFORE 47 PIXEL 47 WISDOM 47 JOURNAL OF 47 Quinamed 47 TRANSFORMS 47 AND RECOMMENDATIONS 47 cabozantinib 47 Refractory Angina 47 Sorafenib HCC Assessment 47 COGENT 47 EORTC 47 EDICT 47 Intervention Effectiveness CATIE 47 ZYBRESTAT TM 47 multicentre 47 Phase III multicenter 47 FINANCIAL MANAGEMENT 47 multicenter randomized controlled 47 CRUSADE 47 viral kinetic 47 Relieve Depression 47 OF EXCELLENCE 47 MIST 47 NCCTG 47 SPEAR 47 OPTIMIZE 47 SORT OUT 47 label multicenter Phase 47 Clinical Antipsychotic Trials 47 GRAVITAS 47 DEFER 47 Microdosing 47 CINQUIL 47 TOPICAL 47 ASCENT 47 Integrium 47 ACTIVE W 47 LIFE SCIENCE 47 INTEGRAL 47 AND SERVE 47 OF CHOICE 47 NSABP 47 EINSTEIN DVT 47 evaluating carfilzomib 47 Randomized Controlled 46 STARTS WITH 46 PLANETS 46 Liraglutide Effect 46 Phase III randomized controlled 46 THAT ARE DIFFICULT TO 46 DECIPHER 46 AVADO 46 STRATUS 46 LEVADEX ™ 46 IMPACTS 46 ZACTIMA 46 pertuzumab 46 OUTCOME 46 First Patient Enrolled 46 Preclinical Study 46 CRISTAL 46 PROACTIVE 46 preclinical efficacy 46 INFORMATION SYSTEMS 46 GLIMPSE 46 READY FOR NEW 46 GEST 46 Anticancer Agent 46 SF #v# 46 ASCO Annual Meeting 46 Biomarker Study 46 CHARM 46 BLACKBOARD 46 BCIRG 46 SIX SIGMA 46 ARBITER 46 HALTS 46 Therapeutic Targets 46 CO ORDINATOR 46 Adjuvant Colon Cancer 46 Chevrolet SILVERADO 46 Evaluation Program CTEP 46 WINDOW OF 46 SLICES 46 REALITY Trial 46 PREPARATORY 46 YOUR DREAMS 46 Adjuvant Breast Cancer 46 ACTOR 'S 46 SEVEN DAY 46 EVEREST II 46 TECHNOLOGIST 46 Ovarian Cancer Screening 46 LUX Lung 46 randomized discontinuation 46 Investigator Initiated 46 SPATIAL 46 EISNER 46 Carotid Revascularization Endarterectomy vs. 46 COSMIC 46 REFLECTIONS OF 46 Clinical Outcome 46 CARDIAC 46 Cholesterol Levels SPARCL 46 THERAPEUTICS 46 MOBILITY 46 Intervention Trial 46 ASCOT 46 VORTEX 46 SCALE 46 COLLABORATION WITH 45 ANNOUNCES PARTNERSHIP WITH 45 ACNP 45 RELAUNCH 45 NEW WAY TO 45 Lifestyle Intervention 45 CLINICAL 45 EXTENDING THE 45 ILLUSTRATE 45 TECHNOLOGY FOR 45 THE REVOLUTION 45 Dr. Pingpank 45 TRADITION OF 45 ExTRACT TIMI 45 EVOLUTION 45 CAPRA 45 lintuzumab 45 RIVIERA 45 BARI 2D 45 Multicenter Phase 45 Dataflow Manager 45 multicenter randomized Phase 45 DEVS 45 BE READY 45 THYROID 45 DIAGNOSTICS 45 TRIAL OF 45 SCIENCE AND 45 INTERACT 45 Clinical Evaluation 45 IN ONTARIO 45 BOOK ON 45 Pharmacokinetic Study 45 Clinical Outcomes Utilizing Revascularization 45 CONQUER 45 ASCO Breast Cancer 45 PROMETHEUS 45 CLL8 45 STAY IN THE 45 'S #TH [002] 45 OF DESPAIR 45 BUSINESS SOLUTIONS 45 BIOMEDICAL 45 DOWNWARD 45 GEEZER 45 Sipuleucel T 45 ENGAGE AF TIMI 45 SERENADE 45 FOR CHANGE 45 ASBMR 45 JOY AT 45 PATENT 45 HYPER 45 Zemplar Capsules 45 RTOG 45 IMAGING 45 BOLDER 45 pharmacokinetic pharmacodynamic PK PD 45 TRAFFIC CONTROL 45 ADJUSTING TO 45 IS EVERYTHING 45 Observational Study 45 RE LY ® 45 ROADMAP 45 ALIGN 45 UPGRADE TO 45 FREEDOMS 45 ASCO abstract 45 RAPTOR 45 MEMORIAL SERVICE FOR 45 THEW 45 PERSEUS 45 OUR WORLD 45 SPECHT 45 CANS 44 Pertuzumab 44 STROLL 44 FRONT RUNNING 44 Algebra Readiness 44 Virtual Histology 44 THE TRACKS 44 STARSHIP 44 MERLIN TIMI 44 Immune Tolerance Network 44 MOMENT OF 44 CELGENE 44 Multicentre 44 SENTINEL 44 assessing T DM1 44 BACCHUS 44 CUPID 44 PLACES TO 44 Glufosfamide 44 GOES GLOBAL 44 ARVO 44 Phase Forward InForm 44 ToGA 44 NUCLEUS 44 YANKEES ARE 44 Study Evaluating 44 AIR2 44 SABCS 44 relapsing multiple sclerosis 44 ISEL 44 CHIMES 44 ADMISSIONS 44 ILLUMINATION 44 PROJECT MANAGEMENT 44 DORE 44 INTERFACE 44 SHADES OF 44 STEP INTO 44 SANDIA 44 AND EARN 44 GENETICS 44 Pre Exposure Prophylaxis 44 EPPS 44 PICASSO 44 PARTNER Trial 44 ONCOLOGY 44 predictive toxicology 44 ABRF 44 Percutaneous Tibial Nerve Stimulation 44 PROactive Study 44 Spine Patient Outcomes 44 INITIATE 44 SEISMIC 44 4EVER 44 HUMAN GENOME SCIENCES 44 3 registrational trial 44 dose escalation clinical 44 MAPPING 44 AMBITION 44 FDA APPROVES 44 THE COLORADOAN 44 CHEMSAS ® 44 JUMP TO 44 INFORMATICS 44 COMPLIANCE 44 IN TRIBUTE TO 44 CLEANS UP 44 Prospective Multicenter 44 TRANS 44 OF CHANGE 44 MOLECULAR 44 RIO Lipids 44 NEW LOOK FOR 44 ALSYMPCA 44 TO RIDE 44 ACCORD Lipid 44 WATCH THIS 44 PHARMACEUTICALS INC 44 TG MV 44 VISITOR 'S 44 POSITIONING 44 CLOSE TO THE 44 CAPELLA 44 ENHANCEMENT 44 CANARY 44 Diabetic Macular Edema DME 44 IS YOURS 44 PERISCOPE 44 PROMS 44 Biodesix 44 Prostate Disease 44 EMBLEM 44 ATMOSPHERIC 44 TWEAK 44 SPECIAL EFFECTS 44 GIVEN GREEN LIGHT 44 DIGITS 44 MiDAS 44 RESEARCH GROUP 44 PITCH FOR 44 Circulatory Support 44 ECASS 44 TAKES FLIGHT 44 RADAR 44 AVAIL 44 ADVANCE 44 SECONDARY SCHOOL 44 RE LY trial 44 GANO 44 CAMMS# 44 orally inhaled migraine 44 WAS MOVING 44 ORAL Solo 44 nonrandomized 44 THE CLASSROOM 44 GOUT 44 WALK TO 44 CATIE 44 ROOM TO 44 TREAT 44 NOT GETTING 44 START UP 44 ROBOTICS 44 Therapeutic Arthritis 44 CONSTRUCT 44 Catabasis 44 BREAKTHROUGH IN 44 OpenMM 44 Clinical Trial Data 44 CHANT 44 Sibutramine Cardiovascular Outcomes 44 AHEAD 44 STUDENTS GET 44 TO SAVE LIVES 44 SKIN CANCER 44 YOUR GOALS 44 PUTIN 'S 44 TO RECOVERY 44 THE VOICE OF 44 ANTEGREN 43 Edge STudy 43 DEPLOY 43 CLARITY study 43 READY FOR THE 43 STATIC 43 Bipolar Depression 43 ENDEAVOR 43 CHOSEN FOR 43 FORTRESS 43 Pediatric Oncology Branch 43 ERYtech 43 HuMax EGFr 43 Treated Patients 43 TRACK RECORD 43 SERUM 43 Therapeutic Potential 43 COMPONENT 43 PUTTING ON 43 NO ORDINARY 43 HORIZONS AMI trial 43 SUTENT ® 43 PROTECT AF 43 CHASM 43 EVALUATIONS 43 Trandolapril 43 Novel Antibody 43 NO MORE EXCUSES 43 VAN DE VELDE 43 INTEGRATED 43 BLOSSOMS 43 PACES 43 SHOOT DOWN 43 ROOM WITH 43 FILLS 43 STRATEGIC ALLIANCE 43 STRIVING FOR 43 BROADEN 43 VALOR trial 43 ADVANCE ILLUMINATE 43 PALOOZA 43 PILOT PROGRAM 43 LETS GET 43 AIRMAN 43 See CLINICAL PHARMACOLOGY 43 ENDORSE 43 vitro ADME 43 Glucosamine Chondroitin Arthritis 43 BY WILLA J. 43 STAGE SET FOR 43 MANAGEMENT SYSTEMS 43 FLASHES 43 MOMENTS OF 43 UT TYLER 43 EORTC NCI 43 Gastrointestinal Cancers Symposium 43 CONSORT 43 VASCULAR 43 MURDOCK Study 43 SIGHTED 43 sunitinib malate 43 GCP compliant 43 Anticancer Drug 43 STROM 43 DRIVEN TO 43 Neoadjuvant Chemotherapy 43 TAPESTRY 43 Chronic Obstructive Lung 43 Laryngeal Cancer 43 DISTRIBUTION AGREEMENT WITH 43 MOSAIC 43 CONTINUING EDUCATION 43 MERGE 43 Placebo Controlled 43 Prolexys 43 ESCAPE 43 Developmental Therapeutics 43 HUGE SUCCESS 43 EMERGE 43 CHARISMA 43 HORIZON 43 ESTEEM 43 Knockout Mouse 43 SPINE 43 Protein Expression 43 INVENT 43 APPRAISE 43 ABSTRACTS 43 GLOBES 43 CONNECTOR 43 WYETH 43 Ziprasidone 43 STRATEGIC PLAN 43 OvPlex ™ 43 Recurrent Glioblastoma 43 TAXUS V 43 TRIGGER 43 PETTIT 43 FETISH 43 SENSORS 43 DEGREE OF 43 INTRUDER 43 BUSINESS INSIDER 43 GOES FOR 43 LUMEN 43 HPTN 43 WORLD CHALLENGE 43 PIER 43 ACCUSED OVER 43 LITHE 43 ASCEND HF 43 CNBC INTERVIEW WITH 43 WE WENT TO 43 PROMPT 43 Baryon Oscillation Spectroscopic Survey 43 INTRODUCES THE 43 teriflunomide 43 HOMME 43 CAPE FEAR 43 CANCER CENTER 43 IIIb 43 COURAGE 43 CAPRIE 43 THEY 'VE GOT 43 FOR THOUGHT 43 ASSESS 43 OF THE FUTURE 43 Diasome 43 HYPERTENSION 43 ADDS UP 43 ASPERA 43 OSLER 43 AVERROES 43 TO BREATHE 43 INNOVATIONS 43 SYMANTEC 43 #th Annual Interscience 43 Women Ischemia Syndrome 43 TOP SEEDS 43 JOIN FORCES 43 Ischemic Stroke 43 CONFERENCING 43 CAMPAIGN LAUNCHED 43 phase III ACCLAIM 43 HCQ 43 GeneSightRx 43 QUEST 43 NEW STUDY 43 JOURNEY OF 43 LOST HIS 43 SCANS 43 DANCE CONCERT 43 ANTICIPATES 43 Pooled Analysis 43 kinase profiling 43 ANTI AGING 43 arzoxifene 43 STRIDE 43 Childhood Asthma 43 HEATS 43 KAPPA 43 FOR TREATMENT 43 Neoadjuvant 43 FILLY 43 MOAT 43 Molecular Genetic 43 Oral Fingolimod 43 Solorel TM 43 omacetaxine mepesuccinate 43 WE NEED MORE 43 REMEDI 43 UNCOMMON 43 PICKED FOR 43 GROWS IN 43 WARFARIN 43 Endovascular System 43 OF DEMOCRACY 43 Comput 43 MEDTRONIC 43 WHERE DOES IT 43 HUMAN CAPITAL 43 YAGER 43 Multicenter Randomized Double 43 RAPID 43 TRANSFORM 43 VOICES FROM THE 43 THE TIRES 43 LEADING EDGE 43 Phase 1b 43 ALL SET TO 43 HEADLIGHTS 43 Syllego system 43 SPACE SHUTTLE 43 SEARCH FOR NEW 43 COCKPIT 43 THE FUTURE IS 43 TRAINING FOR 43 SLACK 43 APPRAISAL 43 Demonstrates Positive 42 IN PATIENTS WITH 42 TOOLS AND 42 IVR IWR 42 FASTRACK 42 Carfilzomib 42 Tumor Microenvironment 42 WALLIAMS 42 Arzerra TM 42 HIM UP 42 Proteasome 42 PREVENT IV 42 AND PARTNER 42 WIDENS 42 AIR AMBULANCE 42 ACOMPLIA R 42 DUSTERS 42 LABORATORY 42 Breaking Clinical Trials 42 oral laquinimod 42 PHASES 42 dual endothelin receptor antagonist 42 FOR HUMANITY 42 THERAPEUTIC 42 LOOKING FOR NEW 42 BRIGHT 42 X RAY 42 PIVOTAL 42 BE PART OF 42 STEM CELL 42 ARE ON 42 SETUP 42 Cannabinoid 42 donepezil Aricept 42 FOUR NATIONS 42 MARKER 42 ASCO GU 42 WHERE ARE WE 42 Stenting Trial 42 FUNCTIONING 42 SCD HeFT 42 REVERSE 42 TERRORS 42 READY FOR BIG 42 RenalGuard System TM 42 Radiation Therapy Oncology 42 BRIGHTER 42 CATCH THE 42 DOUBLE FOR 42 SIMULATOR 42 ASGCT 42 REGISTRY 42 DRAWN TO 42 SPRUCE 42 Niris 42 CANDIDATE 'S 42 RECOVER 42 MERITS 42 ROBBIE 'S 42 EXECUTIVE ASSISTANT 42 WELDING 42 GENOME 42 MARTENS 42 BEST AND BRIGHTEST 42 RENAL 42 EARNS FIRST 42 NEW TECHNOLOGY 42 DRUG DISCOVERY 42 CALLS FOR MORE 42 IF SO WHAT 42 eMR 42 TRAINING PROGRAMME 42 AWARENESS DAY 42 SEARCH FOR THE 42 Teriflunomide 42 CURRENTS 42 TAUGHT ME 42 CURVES 42 Tumor Angiogenesis 42 HOMECARE 42 SJTRI 42 VOCALS 42 KOMEN 42 Microbial Detection 42 Phenotyping 42 Nuclear Receptors 42 neratinib 42 Novel Therapeutics 42 CASCADE 42 TO COMPETE 42 TO BUILD ON 42 PRIME 42 STARRY 42 YOUR BRAIN 42 TOGETHER FOR 42 EXCELLENCE IN 42 OUR BEST 42 ZEAL 42 CONFIRMED FOR 42 CONSIDERED FOR 42 LINEAR 42 CARRA 42 ATLAS 42 PROGRESSION 42 KRN# 42 FALL FASHION 42 RALLIES TO 42 PROSPECT 42 Peregrine Pharma 42 TODAY 'S HIGHLIGHTS 42 LAMICTAL 42 Successfully Completes Phase 42 THE ADOPTION OF 42 FIRED UP FOR 42 IGNORANCE IS 42 QUEST FOR 42 phase 2a 42 SEAD 42 Circulating Tumor Cells 42 CHAMELEON 42 EXPERIMENTS 42 PROSPECTOR 42 GW# [003] 42 GREEN BELT 42 BRAVO 42 PART OF OUR 42 REGISTRATION IS 42 Adaptive Radiation Therapy 42 THE INNER 42 LEGACY OF 42 HORIZONS AMI 42 SOLAR SYSTEM 42 PORTALS 42 HIGH END 42 RED MOUNTAIN 42 KICK START 42 DDW ® 42 Glybera R 42 ADOPT 42 IASLC 42 AWAY DAY 42 EuroScience 42 JASE 42 ANNOUNCES FIRST QUARTER 42 LOUISMO 42 FRIAS 42 WHAT ABOUT YOUR 42 BREAK INTO 42 SHINING 42 ALVESCO HFA 42 LENGTH OF 42 RECRUITER 42 EGIR 42 Artificial Cornea 42 MUSICA 42 HALTER 42 BUSINESS DEVELOPMENT 42 CECH 42 CLINICAL PHARMACOLOGY 42 WOMEN WITH 42 RESIST 42 OUTCOMES 42 ATHENA 42 ONE STEP 42 TECHNOLOGY TO 42 STRUGGLING TO 42 FOOTBALL GAMES 42 GOODBYE TO 42 Vaccine Immunology 42 SERVING UP 42 DENALI 42 SPRINTS 42 ADVANCES IN 42 CHAPTERS 42 PAUL Minn.MN 42 Phase 2b RESTORE CLI 42 MARGO 42 NEW AGE 42 NIBIB 42 CAPRI 42 pharmacokinetic pharmacodynamic 42 INVENTION 42 Bosutinib 42 WORTHY 42 Oncotype DX Recurrence Score 42 VICTORY IS 42 GREEN BUILDING 42 Acute MI 42 Induction Therapy 42 FOR GLORY 42 Amorcyte 42 GETTING YOUR 42 TECHNOLOGY CENTER 42 RESPOND 42 CRIM 42 MORPH 42 Neurotherapeutics 42 STEPS TO 42 GATEWAY TO 42 CLO RP 42 AMYLIN 42 SHOOTING FOR 42 BILLING 42 Cytometry 42 Subgroup Analysis 42 velafermin 42 FORCE PROTECTION 42 ACHIEVERS 42 Prednisone Against Refractory 42 ASCO GI 42 GOLF SOCIETY 42 Mars Climate Sounder 42 WHO TDR 42 NEW TREATMENT 42 Cardiac Outcomes 42 IN NORTH CAROLINA 42 NGLC 42 EARNS TOP 42 RECORD SETTING 42 REMINYL ® 42 SAGE 42 Phase 1b Clinical Trial 42 Hepatitis C Treatment 42 RESIGNS AS 42 Chronic Heart Failure 42 SOCIEDAD 42 SENIOR HEALTH 42 FLARE 42 Novel Approaches 42 STRIDES 42 T2A 42 STUDENT COUNCIL 42 IN YOUR HANDS 42 MODULES 42 SIDEBOTTOM 42 GAMMON GOLD 42 DE ROSSI 42 OPTICS 42 FORECASTING 42 POETIC 42 SWEATS ON 42 BiTE antibody MT# 42 Ellex 2RT 42 Biomarker Discovery 42 MARKS THE 42 BY ANITA 42 Coriell Personalized Medicine 42 Guides FY# Quick Facts 42 DERAIL 42 Clinical Trial Investigating REOLYSIN 42 Multicenter Automatic Defibrillator Implantation 42 IDEAL 42 PUBLIC TRANSIT 42 ON SITE 42 RELATE 42 CADILLAC NEWS 42 Acute Heart Failure 42 SLATES 42 VERONICA 'S 42 Arch Neurol 42 MENTORS 42 Oligonucleotide 42 OMAPRO ™ 41 TASTE FOR 41 COMMERCIAL MANAGER 41 VITAL WIN 41 OPENS AT 41 ANTI DRUG 41 VALIANT 41 COMPUTER SCIENCE 41 CHASERS 41 EMAIL AND 41 COMMENCES 41 COMPOSITE 41 TESTING AND 41 Breast Ultrasound 41 Molecular Basis 41 WAY YOU 41 TECHNOLOGIES CORPORATION 41 WE NEVER 41 SELECT COMMITTEE 41 PSORIASIS 41 varespladib 41 Late Breaker 41 Prognostic Value 41 CANCERS 41 'S EYE 41 FACES TOUGH 41 STUDY SHOWS 41 PROJECTOR 41 UPLIFT 41 Multiscale 41 PUBLIC FORUM 41 ® interferon beta 41 SAFENANO 41 BY CHLOE 41 TLR antagonist 41 ON WAY 41 DO WELL 41 ALARM N 41 STEPS 41 SIGN FOR 41 MODULE 41 IN STORES 41 THE ALL STAR 41 EXCEEDS 41 TONIC 41 Epigenome 41 BrainGate TM 41 MASTERCLASS 41 Romidepsin 41 BUFFER 41 RED LETTER 41 SYMONS 41 RACING POST 41 FAVOURITE FOR 41 REPORT HIGHLIGHTS 41 SPECTRUM 41 MANAGEMENT GROUP 41 rALLy 41 SNAPSHOTS 41 ESTABLISH 41 MAXIMA 41 Lung Injury 41 MARVELS 41 GUINEA PIG 41 NIGHT SKY 41 TrialNet 41 AACR #st Annual Meeting 41 ADVA OPTICAL NETWORKING 41 VISIONS 41 FLIER 41 CURRICULUM 41 CUP HOPES 41 BREEZE 41 Demonstrates Efficacy 41 BLOOD TEST 41 Digestive Diseases Week 41 WHO NEEDS 41 VISUAL 41 BIOTECH 41 CLARA Calif.CA 41 YEARBOOK 41 FALL FROM 41 QUILL